Literature DB >> 22167508

Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

J Hwang1, S H Kim, M W Lee, J Y Lee.   

Abstract

OBJECTIVES: To compare the diagnostic performance of gadoxetic acid-enhanced MRI using 3.0 T with that of multiphasic 64-multirow detector CT (MDCT) for the detection of small (≤2 cm) hepatocellular carcinoma (HCC) in patients with chronic liver disease.
METHODS: A total of 54 patients (44 men, 10 women; age range, 33-81 years) with 59 HCCs (≤2 cm in diameter) who underwent both multiphasic (arterial, portal venous, equilibrium) 64-MDCT and gadoxetic acid-enhanced 3.0 T MRI were enrolled in this study. Two observers independently and randomly reviewed the MR and CT images on a lesion-by-lesion basis. The diagnostic performance of these techniques for the detection of HCC was assessed by alternative free-response receiver operating characteristic (ROC) analysis, in addition to evaluating the sensitivity and positive predictive value.
RESULTS: For each observer, the areas under the ROC curve were 0.874 and 0.863 for MRI, respectively, as opposed to 0.660 and 0.687 for CT, respectively. The differences between the two techniques were statistically significant for each observer (p<0.001). The sensitivities (89.8% and 86.4%) of MRI for both observers were significantly higher than those (57.6% and 61.0% for each observer, respectively) of MDCT. No significant difference was seen between the positive predictive values for the two techniques (p>0.05).
CONCLUSION: Gadoxetic acid-enhanced 3.0 T MRI shows a better diagnostic performance than that of 64-MDCT for the detection of small (≤2 cm) HCCs in patients with chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167508      PMCID: PMC3474077          DOI: 10.1259/bjr/27727228

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  44 in total

Review 1.  3.0-T MR imaging of the abdomen: comparison with 1.5 T.

Authors:  Kevin J Chang; Ihab R Kamel; Katarzyna J Macura; David A Bluemke
Journal:  Radiographics       Date:  2008 Nov-Dec       Impact factor: 5.333

2.  3.0-T MRI evaluation of patients with chronic liver diseases: initial observations.

Authors:  Mauricio Zapparoli; Richard C Semelka; Ersan Altun; Masakatsu Tsurusaki; Ertan Pamuklar; Brian M Dale; Emerson L Gasparetto; Jorge Elias
Journal:  Magn Reson Imaging       Date:  2008-04-28       Impact factor: 2.546

3.  Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.

Authors:  Hye Young Sun; Jeong Min Lee; Cheong Ii Shin; Dong Ho Lee; Sung Kyoung Moon; Kyung Won Kim; Joon Koo Han; Byung Ihn Choi
Journal:  Invest Radiol       Date:  2010-02       Impact factor: 6.016

4.  Small hypervascular hepatocellular carcinomas: value of "washout" on gadolinium-enhanced dynamic MR imaging compared to superparamagnetic iron oxide-enhanced imaging.

Authors:  Jeong-Sik Yu; Jae-Joon Chung; Joo Hee Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2009-06-10       Impact factor: 5.315

5.  Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation.

Authors:  Soon Ho Yoon; Jeong Min Lee; Young Ho So; Sung Hyun Hong; Soo Jin Kim; Joon Koo Han; Byung Ihn Choi
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

6.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Seung Hoon Kim; Jongmee Lee; Min Ju Kim; Yong Hwan Jeon; Yulri Park; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

7.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 8.  MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies.

Authors:  Jonathon M Willatt; Hero K Hussain; Saroja Adusumilli; Jorge A Marrero
Journal:  Radiology       Date:  2008-05       Impact factor: 11.105

9.  Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA.

Authors:  Christoph J Zech; Bernhard Vos; Anders Nordell; Matthias Urich; Lennart Blomqvist; Josy Breuer; Maximilian F Reiser; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2009-06       Impact factor: 6.016

10.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.

Authors:  Renate Hammerstingl; Alexander Huppertz; Josy Breuer; Thomas Balzer; Anthony Blakeborough; Rick Carter; Lluis Castells Fusté; Gertraud Heinz-Peer; Werner Judmaier; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Müller; Koenraad Mortelè; Peter Reimer; Maximilian F Reiser; Philip J Robinson; Kohkan Shamsi; Michael Strotzer; Matthias Taupitz; Bernd Tombach; Gianluca Valeri; Bernhard E van Beers; Thomas J Vogl
Journal:  Eur Radiol       Date:  2007-12-06       Impact factor: 5.315

View more
  28 in total

Review 1.  Solid liver masses: approach to management from the standpoint of a radiologist.

Authors:  Robert Garrett
Journal:  Curr Gastroenterol Rep       Date:  2013-12

Review 2.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

3.  Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study.

Authors:  Mohammad Abd Alkhalik Basha; Mohamad Zakarya AlAzzazy; Ayman F Ahmed; Hala Y Yousef; Samar Mohamad Shehata; Dena Abd El Aziz El Sammak; Talaat Fathy; Ahmed Ali Obaya; Eman H Abdelbary
Journal:  Eur Radiol       Date:  2018-01-24       Impact factor: 5.315

4.  Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.

Authors:  Masakatsu Tsurusaki; Keitaro Sofue; Hiroyoshi Isoda; Masahiro Okada; Kazuhiro Kitajima; Takamichi Murakami
Journal:  J Gastroenterol       Date:  2015-07-01       Impact factor: 7.527

Review 5.  New paradigm for management of hepatocellular carcinoma by imaging.

Authors:  Ijin Joo; Byung Ihn Choi
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 6.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

7.  Study on the diagnosis of small hepatocellular carcinoma caused by hepatitis B cirrhosis via multi-slice spiral CT and MRI.

Authors:  Mei Wang; Congxin Wei; Zhaojuan Shi; Jianzhong Zhu
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

Review 8.  Focal liver lesions: Practical magnetic resonance imaging approach.

Authors:  António P Matos; Fernanda Velloni; Miguel Ramalho; Mamdoh AlObaidy; Aruna Rajapaksha; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-08-08

Review 9.  Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.

Authors:  Tae Wook Kang; Hyunchul Rhim
Journal:  Liver Cancer       Date:  2015-07-17       Impact factor: 11.740

10.  Effect of hepatocyte-specific gadolinium-based contrast agents on hepatic fat-fraction and R2(⁎).

Authors:  Diego Hernando; Shane A Wells; Karl K Vigen; Scott B Reeder
Journal:  Magn Reson Imaging       Date:  2014-10-13       Impact factor: 2.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.